Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 1
2004 12
2005 4
2006 8
2007 4
2008 10
2009 23
2010 26
2011 38
2012 28
2013 38
2014 29
2015 29
2016 35
2017 21
2018 23
2019 52
2020 38
2021 41
2022 28
2023 35
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

471 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean myoung kim (946 results)?
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Lee KY, Xu CR, Massey D, Kim M, Shi Y, Geater SL. Wu YL, et al. Among authors: kim m. Lancet Oncol. 2014 Feb;15(2):213-22. doi: 10.1016/S1470-2045(13)70604-1. Epub 2014 Jan 15. Lancet Oncol. 2014. PMID: 24439929 Clinical Trial.
Cancer epigenetics: Past, present and future.
Lee JE, Kim MY. Lee JE, et al. Semin Cancer Biol. 2022 Aug;83:4-14. doi: 10.1016/j.semcancer.2021.03.025. Epub 2021 Mar 31. Semin Cancer Biol. 2022. PMID: 33798724 Review.
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.
Park K, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, Shi Y, Kim SW, Laskin J, Kim DW, Arvis CD, Kölbeck K, Laurie SA, Tsai CM, Shahidi M, Kim M, Massey D, Zazulina V, Paz-Ares L. Park K, et al. Among authors: kim m. Lancet Oncol. 2016 May;17(5):577-89. doi: 10.1016/S1470-2045(16)30033-X. Epub 2016 Apr 12. Lancet Oncol. 2016. PMID: 27083334 Clinical Trial.
Long non-coding RNAs in cancer.
Kim MY. Kim MY. Noncoding RNA Res. 2019 Feb 21;4(2):45. doi: 10.1016/j.ncrna.2019.02.003. eCollection 2019 Jun. Noncoding RNA Res. 2019. PMID: 31193503 Free PMC article. No abstract available.
Human gut-microbiome-derived propionate coordinates proteasomal degradation via HECTD2 upregulation to target EHMT2 in colorectal cancer.
Ryu TY, Kim K, Han TS, Lee MO, Lee J, Choi J, Jung KB, Jeong EJ, An DM, Jung CR, Lim JH, Jung J, Park K, Lee MS, Kim MY, Oh SJ, Hur K, Hamamoto R, Park DS, Kim DS, Son MY, Cho HS. Ryu TY, et al. ISME J. 2022 May;16(5):1205-1221. doi: 10.1038/s41396-021-01119-1. Epub 2022 Jan 1. ISME J. 2022. PMID: 34972816 Free PMC article.
ESD around the world: Asia.
Kim MY, Cho JH, Jain P, Cho JY. Kim MY, et al. Gastrointest Endosc Clin N Am. 2014 Apr;24(2):283-93. doi: 10.1016/j.giec.2013.11.001. Gastrointest Endosc Clin N Am. 2014. PMID: 24679239 Review.
471 results